Serum and brain concentrations of methylphenidate: Implications for use and abuse

Neuroscience and Biobehavioral Reviews

Volumn 27, Issue 7, 2003, Pages 615-621

  Swanson, J M ^a   Volkow, N D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Abuse; Attention deficit hyperactivity disorder; Clinical use; Dopamine; Pharmacokinetics; Positron emission tomography

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; BEHAVIOR; CONFERENCE PAPER; CONTROLLED DRUG RELEASE; DOSE RESPONSE; DRUG ABUSE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; DRUG TOLERANCE; DRUG UTILIZATION; HUMAN; NERVE CELL; NERVE CONDUCTION; PRIORITY JOURNAL; REINFORCEMENT;

EID: 0242407479     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2003.08.013     Document Type: Conference Paper

References (47)

1. A 14-month Randomized Clinical Trial of Treatment Strategies for Attention Deficit Hyperactivity Disorder. Arch Gen Psychiatry. 56:1999;1073-1086.
2. Swanson J.M., McBurnett K., Wigal T., Pfiffner L.J., Lerner M.A., Williams L., Christian D., Tamm L., Willcutt E., Crowley K., Clevenger W., Khouzam N., Woo C., Crinella F.M., Fisher T.D. Effect of stimulant medication on children with attention deficit disorder: a review of reviews. Exceptional Children. 60:1993;154-162.
3. Swanson J.M., Sergeant J.A., Taylor E., Sonuga-Barke E.J.S., Jensen P.S., Cantwell D.P. Attention-deficit hyperactivity disorder and hyperkinetic disorder. The Lancet. 351:1998;429-433.
4. Swanson J.M., Volkow N. Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav Brain Res. 130:2002;73-78.
5. Volkow N.D., Ding Y., Fowler J.S., Wang G.J., Logan J., Gatley J.S., Dewey S.L., Ashby C., Lieberman J., Hitzemann R., Wolf A.P. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. Arch Gen Psychiatry. 52:1995;456-463.
6. Swanson J.M., Gupta S., Guinta D., Flynn D., Agler D., Lerner M., Williams L., Shoulson I., Wigal S. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther. 66:1999;295-305.
7. Swanson J.M., Cantwell D., Lerner M., McBurnett K., Hanna G. Effects of stimulant medication on learning in children with ADHD. J Learn Disabil. 24:1991;219-230.
8. Greenhill L.L., Swanson J.M., Vitiello B., Davies M., Clevenger W., Wu M., Severe J.B., Arnold L.E., Abikoff H.B., Conners C.K., Elliott G., Hechtman L., Hinshaw S.P., Hoza B., Jensen P.S., Kraemer H.C., March J.S., Newcorn J.H., Pelham W.E., Wells K., Wigal T. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration. Determining the best dose of methylphenidate under controlled conditions: lessons from the MTA titration. J Am Acad Child Adolesc Psychiatry. 40:2001;180-186.
9. Vitiello B., Severe J.B., Greenhill L.L., Arnold L.E., Abikoff H.B., Bukstein O., Elliott G.R., Hechtman L., Jensen P.S., Hinshaw S.P., March J.S., Newcorn J.H., Swanson J.M., Cantwell D.P. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 40:2001;188-196.
10. Swanson J.M., Kinsbourne M., Roberts W., Zucker K. A time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics. 61:1978;21-29.
11. Swanson J.M., Wigal S.B., Greenhill L., Browne R., Waslik B., Lerner M., Williams L., Flynn D., Agler D., Crowley K., Fineberg E., Baren M., Cantwell D. Analog classroom assessment of adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry. 37:1998;519-526.
12. Birmaher B., Greenhill L.L., Cooper T.B., Fried J., Maminski B. Sustained release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry. 28:1989;768-772.
13. Swanson J., Gupta S., Lam A., Shoulson I., Lerner M., Modi N., Lindemulder E., Wigal S. Development of a new once-a-day formulation of methylphenidate for the treatment of ADHD: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 60:2003;204-211.
14. Gonzales M.A., Pentikis H.S., Anderl N., Benedict M.F., DeCory H.H., Dirksen S.J.H., Hatch S.J. Methylphenidate bioavailability from two extended release formulations. Int J Clin Pharmacol Ther. 40:2002;175-184.
15. Swanson J., Greenhill L., Pelham W., Wilens T., Wolraich M., Abikoff H., Atkins M., August G., Biederman J., Bukstein O., Conners C.K., Efron L., Fiebelkorn K., Fried J., Hoffman M., Lambrecht L., Lerner M., Leventhal B., McBurnett K., Morse E., Palumbo D., Pfiffner L., Stein M., Wigal S., Winans E. Initiating concerta (OROS methyphenidate HC1) qd in children with attention-deficit hyperactivity disorder. J Clin Res. 3:2000;59-76.
16. Wolraich M.L., Greenhill L.L., Pelham W., Swanson J., Wilens T., Palumbo D., Atkins M., McBurnett K., Bukstein O., August G., on behalf of the Concerta Study Group. Randomized, Controlled Trial of OROS Methylphenidate Once a Day in Children With Attention-Deficit/Hyperactivity Disorder. Pediatrics. 108:(4):2001;883-892.
17. Greenhill L.L., Findling R.L., Swanson J.M., the MPH MR ADHD Study Group. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 109:2002;E39.
18. Swanson JM, Wigal SB, Wigal T, Soruga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshey-Dirksen SJ, Hatch SJ, COMACS Study Group. Comparison of once-daily extended-release methylphenidate formulations in children with ADHD in the laboratory school (The COMACS Study), in press.
19. Swanson J., Lerner M., Wigal T., Steinhoff K., Greenhill L., Posner K., Freid J., Wigal S. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord. 6:2002;S73-S88.
20. Kuczenski R., Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem. 68:1997;2032-2037.
21. Di Chiara G.D., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci. 85:1988;5274-5278.
22. Parran T.V., Jasinski D.R. Intravenous methylphenidate abuse: prototype for prescription drug abuse. Arch Int Med. 151:1991;781-783.
23. Biederman J., Wilens T., Mick E., Spencer T., Faraone S. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 104:1999;1-5.
24. Wilens T., Faraone S., Biederman J., Gunawardene S. Does the stimulant pharmacotherapy of ADHD beget later substance abuse: a metaanalysis of the literature. Pediatrics. 111:2003;179-185.
25. Bergman J., Madras B., Johnson S.E., Spealman R.D. Effects of cocaine and related drugs in nonhuman primates. III. Self administration by squirrel monkeys. J Pharmacol Exp Ther. 251:1989;150-155.
26. Kollins S.H., MacDonald E.K., Rush C.R. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav. 68:2001;611-627.
27. Llana M.E., Crismon M.L. Methylphenidate: increased abuse or appropriate use? J Am Pharm Assoc. 39:1999;526-530.
28. Johanson C.E., Shuster C.R. A choice procedure for drug reinforcers: cocaine and methylphenidate in the rhesus monkey. J Pharmacol Exp Ther. 193:1975;676-688.
29. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., Hitzemann R., Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 155:1998;1325-1331.
30. Volkow N.D., Wang G.J., Fischman M.W., Foltin R.W., Fowler J.S., Abumrad N.N., Vitkun S., Logan J., Gatley S.J., Pappas N., Hitzemann R., Shea C.E. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 386:1997;827-830.
31. Volkow N.D., Wang G., Fowler J.S., Logan J., Gerasimov M., Maynard L., Ding Y., Gatley S.J., Gifford A., Franceschi D. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 21:2001;RC121.
32. Volkow N.D., Wang G.-J., Fowler J.S., Logan J., Franceschi D., Maynard L., Ding Y.-S., Gatley S.J., Gifford A., Zhu W., Swanson J.M. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse. 43:2002;181-187.
33. Volkow N.D., Wang G.-J., Fowler J.S., Gatley S.J., Logan J., Ding Y.-S., Dewey S.L., Hitzemann R., Gifford A., Pappas N.R. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self reports of 'High'. J Pharmacol Exp Ther. 288:1999;14-20.
34. Solanto M.V. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 94:1998;127-152.
35. Seeman P., Madras B.K. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry. 3:1998;386-396.
36. Wender P. Minimal brain dysfunction in children. 1971;Wiley/Liss, New York.
37. Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust N Z J Psychiatry. 25:1991;277-283.
38. Levy F., Swanson J.M. Timing, space and ADHD: the dopamine theory revisited. Aust N Z J Psychiatry. 35:2001;504-511.
39. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Jayne M., Franceschi D., Wong C., Gatley S.J., Gifford A.N., Ding Y.S., Pappas N. 'Nonhedonic' food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse. 44:2002;175-180.
40. Volkow ND, Wang G-J, Fowler JS, Logan J, Telang F, Jayne M, Wong C, Gatley J, Ding Y-S, Pappas N, Swanson JM. Evidence that Methylphenidate Enhances the Saliency of a Mathematical Task by Increasing Dopamine in the Human Brain. Am. J. Psychiatry. Submitted for review.
41. Volkow ND, Wang GJ, Ma J, Fowler JS, Zhu W, Maynard L, Telang F, Vaska P, Ding YS, Wong C, Swanson JM. Expectation Enhances the Regional Brain Metabolic and the Reinforcing Effects of Stimulants in Cocaine Abusers. J. Neurosci., in press.
42. Volkow N.D., Swanson J.M. Variables that Affect the Clinical Use and Abuse of Methylphenidate. Am J Psychiatry. 2003;. in press.
43. Porrino L.J. Functional consequences of acute cocaine treatment depend on route of administration. Psychopharmacology. 112:1993;343-351.
44. Wightman R.M., Robinson D.L. Transient changes in mesolimbic dopamine and their association with 'reward'. J Neurochem. 82:2002;721-735.
45. Wise R.A. Brain reward circuitry: insights from unsensed incentives. Neuron. 36:2002;229-240.
46. Marsteller D.A., Gerasimov M.R., Schiffer W.K., Geiger J.M., Barnett C.R., Borg J.S., Scott S., Ceccarelli J., Volkow N.D., Molina P.E., Alexoff D.L., Dewey S.L. Acute handling stress modulates methylphenidate-induced catecholamine overflow in the medial prefrontal cortex. Neuropsychopharmacology. 27:2002;163-170.
47. Sonuga-Barke E.J.S. Psychological heterogeneity in AD/HD - a dual pathway model of behavior and cognition. Behav Brain Res. 130:2002;29-36.